A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1

Overview of attention for article published in Clinical Cancer Research, June 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (85th percentile)
Good Attention Score compared to outputs of the same age and source (65th percentile)

So far, Dimensions has found 49 publications that cite this research output.

Article in International Journal of Molecular Sciences (April 2024)

Article in Expert Review of Clinical Immunology (March 2024)

Article in Frontiers in Immunology (February 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.